JP2012107063A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012107063A5 JP2012107063A5 JP2012044260A JP2012044260A JP2012107063A5 JP 2012107063 A5 JP2012107063 A5 JP 2012107063A5 JP 2012044260 A JP2012044260 A JP 2012044260A JP 2012044260 A JP2012044260 A JP 2012044260A JP 2012107063 A5 JP2012107063 A5 JP 2012107063A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- target tumor
- composition according
- target
- inhibitory factor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims 36
- 210000000130 stem cell Anatomy 0.000 claims 32
- 239000008194 pharmaceutical composition Substances 0.000 claims 24
- 102000015278 OSM-LIF Receptors Human genes 0.000 claims 14
- 108010064527 OSM-LIF Receptors Proteins 0.000 claims 14
- 102000004058 Leukemia inhibitory factor Human genes 0.000 claims 12
- 108090000581 Leukemia inhibitory factor Proteins 0.000 claims 12
- 230000011664 signaling Effects 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 7
- 229940079593 drug Drugs 0.000 claims 6
- 102000001893 Bone Morphogenetic Protein Receptors Human genes 0.000 claims 4
- 108010040422 Bone Morphogenetic Protein Receptors Proteins 0.000 claims 4
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 claims 4
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 claims 4
- 229940112869 bone morphogenetic protein Drugs 0.000 claims 4
- 229920000642 polymer Polymers 0.000 claims 4
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims 3
- 239000011324 bead Substances 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 208000005017 glioblastoma Diseases 0.000 claims 3
- 230000001613 neoplastic effect Effects 0.000 claims 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 230000004663 cell proliferation Effects 0.000 claims 2
- 230000004069 differentiation Effects 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 208000014500 neuronal tumor Diseases 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70085905P | 2005-07-19 | 2005-07-19 | |
| US60/700,859 | 2005-07-19 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008522091A Division JP5189977B2 (ja) | 2005-07-19 | 2006-07-19 | Ｌｉｆおよびｂｍｐによる腫瘍性幹細胞の潜在的腫瘍形成能力の抑制 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014262190A Division JP2015057452A (ja) | 2005-07-19 | 2014-12-25 | Ｌｉｆおよびｂｍｐによる腫瘍性幹細胞の潜在的腫瘍形成能力の抑制 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012107063A JP2012107063A (ja) | 2012-06-07 |
| JP2012107063A5 true JP2012107063A5 (enExample) | 2013-01-17 |
| JP5891068B2 JP5891068B2 (ja) | 2016-03-22 |
Family
ID=37420973
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008522091A Expired - Lifetime JP5189977B2 (ja) | 2005-07-19 | 2006-07-19 | Ｌｉｆおよびｂｍｐによる腫瘍性幹細胞の潜在的腫瘍形成能力の抑制 |
| JP2012044260A Expired - Lifetime JP5891068B2 (ja) | 2005-07-19 | 2012-02-29 | Ｌｉｆおよびｂｍｐによる腫瘍性幹細胞の潜在的腫瘍形成能力の抑制 |
| JP2014262190A Withdrawn JP2015057452A (ja) | 2005-07-19 | 2014-12-25 | Ｌｉｆおよびｂｍｐによる腫瘍性幹細胞の潜在的腫瘍形成能力の抑制 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008522091A Expired - Lifetime JP5189977B2 (ja) | 2005-07-19 | 2006-07-19 | Ｌｉｆおよびｂｍｐによる腫瘍性幹細胞の潜在的腫瘍形成能力の抑制 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014262190A Withdrawn JP2015057452A (ja) | 2005-07-19 | 2014-12-25 | Ｌｉｆおよびｂｍｐによる腫瘍性幹細胞の潜在的腫瘍形成能力の抑制 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US9220756B2 (enExample) |
| EP (2) | EP3117833B1 (enExample) |
| JP (3) | JP5189977B2 (enExample) |
| KR (2) | KR101311061B1 (enExample) |
| AU (1) | AU2006271308B2 (enExample) |
| CA (2) | CA2615491C (enExample) |
| DK (2) | DK3117833T3 (enExample) |
| ES (2) | ES2686093T3 (enExample) |
| HR (1) | HRP20181379T1 (enExample) |
| HU (2) | HUE042197T2 (enExample) |
| NZ (2) | NZ565172A (enExample) |
| PL (2) | PL3117833T3 (enExample) |
| WO (1) | WO2007010394A2 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3117833T3 (en) * | 2005-07-19 | 2019-03-18 | Stemgen S P A | Inhibition of Tumor-rich Potential of Tumor Stem Cells with LIF |
| US8361955B2 (en) | 2008-02-13 | 2013-01-29 | Dkfz Deutsches Krebsforschungszentrum, Stiftung Des Offentlichen Rechts | Methods for treating and preventing brain tumors based on bone morphogenetic proteins |
| CA2995310A1 (en) | 2015-08-25 | 2017-03-02 | Histide Ag | Compounds for inducing tissue formation and uses thereof |
| EP3349778B1 (en) * | 2015-09-17 | 2021-09-01 | Histide AG | Pharmaceutical association of growth factor receptor agonist and adhesion protein inhibitor for converting a neoplastic cell into a non-neoplastic cell and uses thereof |
| KR20180050744A (ko) * | 2015-09-17 | 2018-05-23 | 히스티드 아게 | 신생물성 세포를 비-신생물성 세포로 전환시키기 위한 약제학적 회합물 및 이것의 용도 |
| KR20180052705A (ko) * | 2015-09-17 | 2018-05-18 | 히스티드 아게 | 신생물성 세포를 비-신생물성 세포로 전환시키기 위한 약제학적 회합물 및 이것의 용도 |
| WO2017046226A2 (en) * | 2015-09-17 | 2017-03-23 | Histide Ag | Pharmaceutical association for converting a neoplastic cell into a non-neoplastic cell and uses thereof. |
| CA2998677A1 (en) * | 2015-09-17 | 2017-03-23 | Histide Ag | Pharmaceutical association for converting a neoplastic cell into a non-neoplastic cell and uses thereof |
| WO2020138503A1 (ja) * | 2018-12-28 | 2020-07-02 | 国立大学法人 東京大学 | 神経膠腫の治療および予防剤、脳腫瘍の悪性度のマーカーおよび脳腫瘍の予後マーカー、脳腫瘍の悪性度および予後の判定方法並びに腫瘍増殖を抑制する抗体 |
| WO2026022122A1 (en) * | 2024-07-23 | 2026-01-29 | Eos Research Sa | Checkpoint inhibitors in the treatment of glioblastoma multiforme |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5506337A (en) | 1985-03-15 | 1996-04-09 | Antivirals Inc. | Morpholino-subunit combinatorial library and method |
| US5010175A (en) | 1988-05-02 | 1991-04-23 | The Regents Of The University Of California | General method for producing and selecting peptides with specific properties |
| US5328470A (en) | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| US5324519A (en) * | 1989-07-24 | 1994-06-28 | Atrix Laboratories, Inc. | Biodegradable polymer composition |
| GB9004890D0 (en) * | 1990-03-05 | 1990-05-02 | Heath John K | Leukaemia inhibitory factor |
| IE66205B1 (en) | 1990-06-14 | 1995-12-13 | Paul A Bartlett | Polypeptide analogs |
| US5650489A (en) | 1990-07-02 | 1997-07-22 | The Arizona Board Of Regents | Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof |
| CA2104576C (en) * | 1991-12-24 | 1997-04-15 | George Kannourakis | A method for the treatment of tumours and sarcomas |
| US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| US5288514A (en) | 1992-09-14 | 1994-02-22 | The Regents Of The University Of California | Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support |
| US7592428B1 (en) * | 1992-11-17 | 2009-09-22 | Ludwig Institute For Cancer Research | Antibodies which bind specifically to activin receptor like kinases |
| US5519134A (en) | 1994-01-11 | 1996-05-21 | Isis Pharmaceuticals, Inc. | Pyrrolidine-containing monomers and oligomers |
| US5593853A (en) | 1994-02-09 | 1997-01-14 | Martek Corporation | Generation and screening of synthetic drug libraries |
| US5539083A (en) | 1994-02-23 | 1996-07-23 | Isis Pharmaceuticals, Inc. | Peptide nucleic acid combinatorial libraries and improved methods of synthesis |
| EP0756628B1 (en) * | 1994-04-29 | 2007-11-14 | Curis, Inc. | Morphogenic protein-specific cell surface receptors and uses therefor |
| US5525735A (en) | 1994-06-22 | 1996-06-11 | Affymax Technologies Nv | Methods for synthesizing diverse collections of pyrrolidine compounds |
| US5549974A (en) | 1994-06-23 | 1996-08-27 | Affymax Technologies Nv | Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof |
| US6281015B1 (en) * | 1994-12-16 | 2001-08-28 | Children's Medical Center Corp. | Localized delivery of factors enhancing survival of transplanted cells |
| US20010053371A1 (en) * | 1999-01-07 | 2001-12-20 | Waldemar Debinski | Method for diagnosing, imaging, and treating tumors using restrictive receptor for interleukin 13 |
| US5804162A (en) | 1995-06-07 | 1998-09-08 | Alliance Pharmaceutical Corp. | Gas emulsions stabilized with fluorinated ethers having low Ostwald coefficients |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5569588A (en) | 1995-08-09 | 1996-10-29 | The Regents Of The University Of California | Methods for drug screening |
| US6036920A (en) | 1996-05-09 | 2000-03-14 | 3-Dimensional Pharmaceuticals, Inc. | Microplate thermal shift assay apparatus for ligand development and multi-variable protein chemistry optimization |
| JP4892131B2 (ja) * | 1998-11-13 | 2012-03-07 | ストライカー コーポレイション | 癌の症状を緩和する方法 |
| EP1246617B1 (en) * | 1999-12-06 | 2006-09-13 | Rhode Island Hospital | Use of taurolidine or taurultam for the manufacture of a medicament for the treatment of ovarian cancer |
| US20030162700A1 (en) * | 2000-03-03 | 2003-08-28 | Shipham Kylie Ann-Maree | Method of treatment |
| WO2005026382A1 (en) | 2003-09-12 | 2005-03-24 | Stemcell Technologies Inc. | Neural colony forming assay |
| JP2005098727A (ja) | 2003-09-22 | 2005-04-14 | Hosiden Corp | 振動センサ |
| CA2546465A1 (en) | 2003-12-05 | 2005-06-23 | The Board Of Trustees Of The Leland Stanford Junior University | Identification, isolation and elimination of cancer stem cells |
| EP2789342A1 (en) * | 2004-06-17 | 2014-10-15 | Thrasos Innovation, Inc. | TDF-related compounds and analogs thereof |
| DK3117833T3 (en) * | 2005-07-19 | 2019-03-18 | Stemgen S P A | Inhibition of Tumor-rich Potential of Tumor Stem Cells with LIF |
| ES2363358B1 (es) * | 2009-04-03 | 2012-06-21 | FUNDACIÓ INSTITUT DE RECERCA HOSPITAL UNIVERSITARI VALL D'HEBRON (Titular al | Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable. |
| EP2371860A1 (en) * | 2010-04-05 | 2011-10-05 | Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron | Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation |
| JO3421B1 (ar) | 2011-06-20 | 2019-10-20 | H Lundbeck As | طريقة لإعطاء 1-((1ار.3س)-6-كلورو-3-فينيل-اندان-1-ايل)-1.2.2-ترايميثيل- بيبيرازين واملاجها لمعالجة انفصام الشخصية |
| WO2015050844A1 (en) * | 2013-10-01 | 2015-04-09 | Dana-Farber Cancer Institute, Inc. | Methods of treating cancer with atovaquone-related compounds |
-
2006
- 2006-07-19 DK DK16171392.0T patent/DK3117833T3/en active
- 2006-07-19 WO PCT/IB2006/002296 patent/WO2007010394A2/en not_active Ceased
- 2006-07-19 CA CA2615491A patent/CA2615491C/en not_active Expired - Lifetime
- 2006-07-19 EP EP16171392.0A patent/EP3117833B1/en not_active Expired - Lifetime
- 2006-07-19 JP JP2008522091A patent/JP5189977B2/ja not_active Expired - Lifetime
- 2006-07-19 PL PL16171392T patent/PL3117833T3/pl unknown
- 2006-07-19 EP EP06795317.4A patent/EP1904093B1/en not_active Expired - Lifetime
- 2006-07-19 ES ES06795317.4T patent/ES2686093T3/es not_active Expired - Lifetime
- 2006-07-19 NZ NZ565172A patent/NZ565172A/xx unknown
- 2006-07-19 KR KR1020127028173A patent/KR101311061B1/ko not_active Expired - Lifetime
- 2006-07-19 DK DK06795317.4T patent/DK1904093T3/en active
- 2006-07-19 CA CA2790675A patent/CA2790675C/en not_active Expired - Lifetime
- 2006-07-19 HU HUE16171392A patent/HUE042197T2/hu unknown
- 2006-07-19 AU AU2006271308A patent/AU2006271308B2/en not_active Expired
- 2006-07-19 HU HUE06795317A patent/HUE040063T2/hu unknown
- 2006-07-19 ES ES16171392T patent/ES2710601T3/es not_active Expired - Lifetime
- 2006-07-19 PL PL06795317T patent/PL1904093T3/pl unknown
- 2006-07-19 US US11/996,214 patent/US9220756B2/en active Active
- 2006-07-19 NZ NZ598031A patent/NZ598031A/xx unknown
- 2006-07-19 HR HRP20181379TT patent/HRP20181379T1/hr unknown
- 2006-07-19 KR KR1020087003552A patent/KR101338533B1/ko not_active Expired - Lifetime
-
2012
- 2012-02-29 JP JP2012044260A patent/JP5891068B2/ja not_active Expired - Lifetime
-
2014
- 2014-12-25 JP JP2014262190A patent/JP2015057452A/ja not_active Withdrawn
-
2015
- 2015-11-16 US US14/942,157 patent/US9737589B2/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sun et al. | Bone-targeted nanoplatform combining zoledronate and photothermal therapy to treat breast cancer bone metastasis | |
| Hucklenbroich et al. | Aromatic-turmerone induces neural stem cell proliferation in vitro and in vivo | |
| Zorzi et al. | A phase I study of histone deacetylase inhibitor, pracinostat (SB939), in pediatric patients with refractory solid tumors: IND203 a trial of the NCIC IND program/C17 pediatric phase I consortium | |
| WO2021053667A3 (en) | Combination cancer therapy and cytokine control therapy for cancer treatment | |
| NZ707377A (en) | Combination therapy methods for treating proliferative diseases | |
| MY199967A (en) | Combinations of lsd1 inhibitors for use in the treatment of solid tumors | |
| JP2014530220A5 (enExample) | ||
| JP2016517888A5 (enExample) | ||
| NZ708506A (en) | Methods of treating bladder cancer | |
| JP2009539769A5 (enExample) | ||
| Ren et al. | Photoresponsive blood-derived protein hydrogels packed with bioactive carbon dots modulate mitochondrial homeostasis and reprogram metabolism for chronic wound healing in diabetes | |
| BR112016013026A2 (pt) | compostos para receptor-3 de fator de crescimento de fibroblasto (fgfr3) e métodos de tratamento | |
| WO2016210376A3 (en) | Therapeutic peptides and methods of use thereof | |
| JP2018048151A5 (enExample) | ||
| BR112014029954A2 (pt) | tratamento de tumores sólidos usando coenzima q10 | |
| JP2019526559A5 (enExample) | ||
| CN110248671A (zh) | 包含溶瘤痘病毒和nk细胞的治疗剂及其在治疗肿瘤和/或癌症的药物中的应用 | |
| CN110062628A (zh) | 一种瑞卡帕布口服缓控释药物组合物及其用途 | |
| TW201313228A (zh) | Ｎ－羥基－４－｛２－［３－（ｎ，ｎ－二甲基胺基甲基）苯並呋喃－２－基羰基胺基］乙氧基｝苯甲醯胺之新穎投藥法 | |
| Peng et al. | Thermosensitive injectable hydrogel enhances the antitumor effect of embelin in mouse hepatocellular carcinoma | |
| JP2016515550A5 (enExample) | ||
| CN109983015A (zh) | 6-吡唑-[1,2,4]三唑并[4,3-a]吡啶-3-酰胺类衍生物、其制备方法及其在医药上的应用 | |
| CA2736751A1 (en) | Salts of n-[6-(cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-3-carboxamide | |
| JP2009510165A5 (enExample) | ||
| BRPI0715609A2 (pt) | Composto, uso de um composto, métodos para produzir um efeito antiproliferativo em um animal de sangue quente, e para tratar uma doença em um animal de sangue quente, e, composição farmacêutica |